Objective. Intraarticular glucocorticoid injections are common in rheumatoid arthritis (RA) treatment. This study was undertaken to investigate whether ultrasound in combination with clinical examination is better than clinical examination alone at identifying joints that will benefit from intraarticular injections, and to compare the efficacy of ultrasound-guided versus palpation-guided procedures.
to ultrasound findings at the time of injection, supporting the use of ultrasound as a tool to select joints that will benefit from intraarticular injections. However, ultrasound needle guidance was not superior to palpation guidance.
Rheumatoid arthritis (RA) is a chronic systemic and potentially disabling disease. Modern treatment of RA includes treat-to-target strategies with disease-modifying antirheumatic drugs (DMARDs) (1, 2) . In addition, intraarticular glucocorticoid injections are part of RA treatment in many countries. Previous studies have indicated that the addition of intraarticular glucocorticoid injections results in better clinical outcomes (3) (4) (5) (6) (7) . The Cyclosporine, Methotrexate, Steroid in RA (CIMESTRA) study showed that intraarticular glucocorticoid injections in combination with methotrexate in a treat-to-target strategy of early RA resulted in inflammatory control. However, there was no control group that did not receive injections in that study (3) . One study showed that inflammatory activity assessed by ultrasound decreased after intraarticular glucocorticoid injections, while another found no changes on ultrasound or magnetic resonance imaging after injections (8, 9) . Glucocorticoid injections have been associated with few side effects and have also been shown to protect against periarticular bone loss in RA (10, 11) .
Ultrasound is increasingly applied in RA management, and use of ultrasound to guide injections is standard practice in several countries. Ultrasound guidance is performed indirectly by skin surface marking or under direct sonographic guidance (12) . Several studies, clinical and in cadavers, have demonstrated better accuracy with ultrasound-guided compared to palpation-guided injection procedures (13) . However, studies are limited and conflicting when it comes to whether use of ultrasound guidance improves clinical outcomes (13) . One study showed that sonographic needle guidance improved clinical outcomes of intraarticular injections for inflammatory arthritis (14) . Naredo et al found greater improvement in pain and shoulder function with ultrasound-guided compared to palpation-guided injections for painful shoulder (15) . However, a Cochrane review did not show any advantage in terms of clinical outcomes of ultrasound-guided glucocorticoid injection for shoulder disorders over either landmark-guided or intramuscular injections (16) .
Ultrasound can also be used as a tool in deciding whether or not to inject a joint (17) . There is a discrepancy between clinical and ultrasound assessment of synovitis at the joint level (18) , but there is little knowledge about how this influences the selection of, and ultimately effect of, injections in RA joints. We are not aware of any previous study addressing whether the effect of glucocorticoid injections varies in joints with different clinical and ultrasound findings.
We have previously shown that the addition of structured ultrasound assessment to a treatment strategy targeting subclinical inflammation did not improve patient outcomes in Aiming for Remission in Rheumatoid Arthritis: a Randomised Trial Examining the Benefit of Ultrasonography in a Clinical Tight Control Regimen (ARCTIC) (19) . Additionally, the Targeting Synovitis in Early Rheumatoid Arthritis (TASER) study concluded that the use of ultrasound did not improve a clinical treatto-target strategy (20) . Even though structured ultrasound has not been proven to add to aggressive tight control treatment, ultrasound may be useful in optimizing intraarticular injection therapy.
The objective of the present study was to investigate whether a combination of ultrasound and clinical examination is better than clinical examination alone at identifying joints that will benefit from intraarticular injections. Additionally, we compared the efficacy of ultrasound-guided versus palpation-guided injection procedures.
PATIENTS AND METHODS
Patients. The main inclusion criteria of the ARCTIC trial (ClinicalTrials.gov identifier: NCT01205854) were an age of 18-75 years, fulfillment of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA (21) , less than 2 years of symptom duration from the first swollen joint, and indication for DMARD treatment without prior DMARD use. All patients provided written informed consent.
Study design. Patients were randomized 1:1 to a treatto-target strategy with or without ultrasound (19) . The same DMARD escalation algorithm was applied in both strategy groups, and clinically swollen joints were treated with intraarticular glucocorticoids (triamcinolone hexacetonide). In the ultrasound strategy group, an additional target was non-swollen joints with power Doppler (PD) activity, and injections were performed with an ultrasound-guided needle placement technique. In the conventional strategy group, injections were palpationguided and performed by experienced rheumatologists. None of the rheumatologists in the conventional strategy group were sonographers. Injection of tender joints (without swelling or PD activity) was not allowed in either study group. Patients were assessed at 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20 , and 24 months, and injections were allowed at all visits. The maximum dose of triamcinolone hexacetonide was 80 mg per visit, distributed across joints as decided by the treating rheumatologist.
The trial was conducted at 11 centers in Norway between 2010 and 2015, in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice.
Assessments. Data collected included demographic information, anti-citrullinated protein antibody (ACPA) and rheumatoid factor status, erythrocyte sedimentation rate (mm/hour), C-reactive protein level (mg/liter), Ritchie Articular Index (22) , swollen joint count in 44 joints, the patient's and physician's global assessments of disease activity on 0-100-mm visual analog scales, patient-reported outcome measures, and radiographs of the hands and feet, scored according to the modified Sharp/van der Heijde score (23) . The Disease Activity Score (DAS) was calculated (24) .
An extensive ultrasound examination was performed using a validated semiquantitative scoring system of 0-3 for both gray-scale ultrasound and PD. The joints included were metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 2 and 3, the radiocarpal joint, intercarpal joint, distal radioulnar joint, elbow, knee, talocrural joint, and metatarsophalangeal (MTP) joints 1-5. Ultrasound examinations were performed according to a previously published scoring system that has shown good inter-and intraobserver reliability (25) . All sonographers underwent systematic training. Siemens Antares or GE Logiq E9 machines with linear probes were used, and PD parameters were adjusted according to the device used (26) .
In the ultrasound strategy group, patients underwent ultrasound examination at all visits. Patients in the conventional strategy group were examined by ultrasound at baseline, 12 months, and 24 months, and both patient and treating physician were blinded with regard to the results. All patients were assessed for clinical joint swelling at all visits, with clinical joint examination performed prior to any ultrasound examination.
Statistical analysis. Baseline patient characteristics are expressed as the number (%), mean AE SD, or median (25th, 75th percentiles) as appropriate. We assessed the distribution of injections in patients followed up with ultrasound and those followed up without ultrasound, and compared proportions of patients with any injection by means of logistic regression, adjusting for sex due to sex imbalance between the groups. Frequencies of injections were compared between groups using the chi-square test.
Next, we examined whether clinical and ultrasound findings were associated with subsequent clinical joint swelling. To assess the effect of the systemic treatment, we used only uninjected joints, and calculated the risk of joint swelling at the next visit according to current swelling and ultrasound inflammation status. Separately for swollen and non-swollen joints, we estimated the odds ratio (OR) of a joint being swollen at the next visit in joints with different PD scores (0, 1, 2, or 3), compared to non-swollen joints with no PD activity (PD score of 0). This was accomplished using a logistic mixed-effects model with random intercepts for patient and joint in order to account for associations between responses from the same patient or joint. We adjusted models for age, sex, ACPA status, and strategy group (follow-up with or without ultrasound). We also adjusted for whether the patient was assessed at the baseline visit or at subsequent visits, since patients started bridging therapy with 15 mg prednisolone at baseline. Data from the 2 strategy groups were pooled and analyzed together, since clinical and radiographic outcomes were similar in the 2 groups after 2 years (19) .
The efficacy of injections in joints with different clinical and ultrasound findings was subsequently examined. Treatment success was defined as the joint being classified as non-swollen on clinical examination at the next visit. In order to avoid selection bias, we compared injected and uninjected joints with identical PD score (0, 1, 2, or 3) and swelling status (swollen or nonswollen) at the time point of injection decision. A logistic mixedeffects model with random intercepts by patient and joint was used. We included all visits and adjusted for the time of injection decision, stratified as decision performed "at baseline visit" or "at subsequent visits." All models were adjusted for age, sex, ACPA status, and strategy group. We also performed robustness analysis excluding the baseline visit, and models with adjustments for DAS, time between visits and systemic treatment, including prednisolone and type of DMARD.
Finally, we compared the efficacy of intraarticular injections administered with ultrasound guidance versus those administered with palpation guidance. We conducted the efficacy analysis described above for baseline and 1 year, the time points when all patients were examined with ultrasound, adding the interaction between injection (yes/no) and strategy group (ultrasound/conventional). We then used marginal means to describe the difference in treatment success between ultrasound-guided and palpation-guided injections. In robustness analyses, we included all swollen joints, regardless of ultrasound assessment. In analyses requiring ultrasound data at the joint level, data were available for MCP joints 1-5, PIP joints 2 and 3, radiocarpal, intercarpal, elbow, knee, and talocrural joints, and MTP joints 1-5. Statistical analyses were performed using Stata version 14 (StataCorp) . No imputation of missing data was done.
RESULTS
Baseline characteristics and disposition of the patients. Two hundred and thirty patients were included (118 in the ultrasound strategy group and 112 in the conventional strategy group). The mean AE SD age was 50.6 AE 13.3 years in the ultrasound group and 52.3 AE 14.1 years in the conventional strategy group. In the ultrasound group 71% of the patients were women, and in the conventional strategy group 51% of the patients were women. The mean DAS corresponded to moderate disease activity in both groups (Table 1 ). The 2 groups were well balanced overall with regard to baseline characteristics with the exception of sex (Table 1) . Full baseline characteristics and trial profile have been published previously (19, 27) .
Distribution of injections. A total of 1,318 glucocorticoid injections were administered during the study. Of these, 1,103 were first-time injections in a joint (627 in the ultrasound group and 476 in the conventional strategy group), 163 were second-time injections (108 in the ultrasound group and 55 in the conventional strategy group), and 52 were third-time or later injections (35 in the ultrasound group and 17 in the conventional strategy group). More patients in the ultrasound group received injections during the study than in the conventional strategy group, especially in the intercarpal and MTP joints ( Table 2 ). The number of injections at the baseline visit was similar in the 2 groups (78 versus 94; P = 0.12) (Table 1) , while more injections occurred in the ultrasound group at subsequent visits (692 versus 454; P < 0.001).
Prediction of clinical joint swelling. The risk of clinical joint swelling at the next visit in uninjected joints increased with grade of PD activity, both in swollen and non-swollen joints (Table 3) . * OR = odds ratio; 95% CI = 95% confidence interval; DIP = distal interphalangeal; PIP = proximal interphalangeal; MCP = metacarpophalangeal; IP = interphalangeal; MTP = metatarsophalangeal. † Adjusted for sex. Efficacy of injecting joints based on ultrasound and clinical findings. More patients benefitted from glucocorticoid injections in swollen and non-swollen joints with moderate PD activity than from injections in joints with no or low PD activity. The number of joints that needed to be injected to prevent 1 swollen joint at the next visit was lowest for injections in swollen joints with a PD score of 2, with a number of joints that needed to be injected of 6, based on adjusted values. The efficacy of injecting clinically swollen joints without PD activity was small and not statistically significant (Table 4) . Exclusion of the first visit from the analyses revealed similar results; the efficacy of injections was somewhat better and the number of joints that needed to be injected was smaller (the lowest number of joints that needed to be injected was 5, in swollen joints with a PD score of 2). Also in this analysis, there was no statistically significant efficacy of injecting swollen joints without PD activity. Sensitivity analyses adjusted for DAS, time between visits, and systemic treatment, including prednisolone and type of DMARD, did not substantially change the results (data not shown).
Efficacy of the ultrasound-guided procedure. In the ultrasound group, 285 clinically swollen joints were injected during the study, whereas 338 clinically swollen joints were injected in the conventional strategy group. The success rate of these injections (in terms of nonswollen joint at next visit) was similar across groups (marginal predicted mean [25th, 75th percentiles] 0.83 [0.78, 0.88] in the ultrasound group and 0.88 [0.85, 0.92] in the conventional strategy group; P = 0.17). The marginal predicted means of successful injection in joints with identical PD activity and swelling state at the time of injection were similar when performed with or without ultrasound guidance (Table 5) .
DISCUSSION
This study highlights the fact that ultrasound may be important in clinical decision-making regarding whether or not to administer an intraarticular injection. We found PD activity to be strongly associated with clinical joint swelling at the next visit in uninjected joints. Better efficacy was observed for glucocorticoid injections in joints with a PD signal than in joints without a PD signal, and the efficacy of injecting clinically swollen joints without a PD signal was small and not statistically significant. The efficacy of injections was similar whether they were administered with or without ultrasound needle guidance. * OR = odds ratio; 95% CI = 95% confidence interval; PD = power Doppler; NA = not applicable. † Treatment was considered a success when the joint was not swollen at the next visit. ‡ Adjusted for associations between responses from the same patient or joint, sex, age, anti-citrullinated protein antibody status, time of injection (visit 1 or subsequent visits), and strategy group. § Injections in non-swollen joints without ultrasound findings were not allowed according to the protocol. ¶ Not estimable (NE) due to convergence issues. * Values are the marginal predicted mean (25th, 75th percentiles) (no. of joints with treatment success/no. of injected joints). Analyses were adjusted for associations between responses from the same patient or joint, sex, age, anti-citrullinated protein antibody status, time of injection (baseline or 12 months), and strategy group. There were no significant differences between groups. PD = power Doppler; NE = not estimable.
NORDBERG ET AL
A previous study showed that ultrasound frequently led the physician to change the decision of whether to administer an injection into painful foot joints in patients with rheumatic diseases. In that study such modifications were associated with a trend toward improved short-term symptomatic treatment effect (17) . The study did not examine which ultrasound or clinical findings influenced the decision to inject or not, or which findings were associated with a good outcome at the next visit. In a clinical setting, it is important to know which joints to inject to achieve the best effect. According to our results, injections in both swollen and non-swollen joints with moderate PD activity were beneficial, while there was no benefit to injecting joints without PD activity.
In the present study, the efficacy of injecting a joint was best if the joint had a PD score of 2 at the time of injection. This may be explained by the chance of improvement in joint swelling in joints with different grades of ultrasound synovitis without intraarticular injections. When PD activity was low (score of 0-1), the probability of a non-swollen joint at the next visit was also high if the joint was not injected, leading to a lower OR. Also, according to our results, injections in joints with the highest grade of inflammation (swollen and a PD score of 3) were not the most effective. A potential explanation might be that inflammation is so severe that one injection is not sufficient, but the limited number of observations makes interpretation difficult.
Our findings suggest that the effect of intraarticular injections depends on both clinical and ultrasound findings at the time of injection, and ultrasound seems to be a valuable tool to select the optimal joints for injections. However, even if joints are selected optimally, the number of joints that need to be injected to prevent one swollen joint may be high. In our study the number of joints that needed to be injected to prevent 1 swollen joint at the next visit was lowest for injections in swollen joints with a PD score of 2, with a number of joints that needed to be injected of 6, based on adjusted values. Systemic treatment with a treat-to-target and tight control strategy leads to reduction and prevention of joint swelling in most joints, even if they are not injected. The number of joints that needed to be injected was somewhat lower when injections were performed after the first visit, probably because patients received oral prednisolone at the first visit. This may indicate that during bridging with oral prednisolone, the clinical relevance of injections may be questionable.
However, we cannot rule out the possibility that our comparison of injected and uninjected joints is biased. Even though we compared joints with identical PD score in order to limit selection bias, injected joints may have had more severe inflammation to be selected for injection by the rheumatologist. This may have resulted in a lower estimated efficacy than the true effect. We are not aware of any randomized controlled trial comparing the effect of intraarticular injection versus placebo/no injection in RA patients receiving modern treat-to-target therapy. In our study, we selected joint swelling at the next visit as the outcome measure; thus, we cannot rule out the possibility that the treatment effect in injected joints was faster than that in joints receiving only systemic treatment. Previous studies have shown response to intraarticular glucocorticoids after less than 2 weeks (3, 28) .
In the ARCTIC trial, more injections were administered in the ultrasound strategy group. This is not surprising since the rheumatologists were instructed to inject clinically swollen joints in both strategy groups, but also to inject joints with PD signal in the ultrasound strategy group. The use of ultrasound may lead to an increased number of injections, and possibly to overtreatment, if the physician chooses to inject all clinically swollen joints and additionally all joints with subclinical synovitis. However, the application of ultrasound may also lead to a decreased number of injections. According to our results, injections in clinically swollen joints without PD activity and nonswollen joints with low PD activity were not effective; 34% of the injected joints included in our analyses belong in this category, and should probably not have been injected. Our results suggest that if ultrasound is used as a tool to restrict injections to the joints most likely to benefit, it will not lead to overtreatment, but rather to avoidance of unnecessary injections and optimization of injection therapy.
Based on previously published studies, ultrasound may be useful for needle guidance, but findings are conflicting. Several studies have shown that ultrasound guidance increases accuracy, but this may depend on the clinician's experience (13) . In one study, ultrasound did not increase the accuracy of wrist injections when palpation-guided injections were performed by experienced rheumatologists (29) . In our study palpation-guided injections were performed by experienced rheumatologists. In clinical practice, ultrasound guidance may be a helpful tool for less experienced clinicians. Ultrasound-guided injection may involve a less complex learning curve compared to that necessary for an optimal palpation-guided procedure. A previous study showed that a trainee performing ultrasound-guided injections rapidly achieved higher accuracy than experienced rheumatologists performing palpation-guided injections. That study also showed that accurate injections did improve clinical outcomes and that ultrasound-guided injections were more accurate, but ultrasound guidance still did not improve the short-term outcome of joint injection (30) . As in these previous publications, the efficacy of injections in the current analyses was similar when administered with or without ultrasound guidance. Overall, there is not convincing evidence of a clinically relevant difference in efficacy between ultrasound-guided and palpation-guided injection procedures.
Our study has some limitations. In the ARCTIC trial, the rheumatologists were instructed to inject clinically swollen joints regardless of ultrasound findings in both groups. We therefore could not study the efficacy of selecting joints with ultrasound simply by comparing efficacy across study groups. In order to avoid selection bias in our efficacy analyses, we compared injected and uninjected joints with identical PD score and clinical joint swelling state. Our selection of joints therefore depended on available ultrasound data. Ultrasound information was available for all visits in the ultrasound group only, and even though we have adjusted for this, there may have been selection bias. Also, for some of the selected joints, the number available for analyses was low, resulting in large confidence intervals. The strengths of our study include extensive data collection aiming to include all patients newly diagnosed as having RA at the participating centers with clinical and ultrasound examinations of all patients. The number of joints included in our analyses and the number of intraarticular injections administered during the study were extensive. Knowledge of which joints are most likely to respond to injections with glucocorticoids in RA patients is important, but information is absent in the literature. This is the first study examining the effect of intraarticular injections in joints with different clinical and ultrasound findings.
Our results indicate that ultrasound assessment combined with clinical examination is superior to clinical examination alone in identifying joints that will benefit from intraarticular injections. However, the efficacy of injections was similar when guided by ultrasound or palpation. In our study of patients with early RA receiving systemic DMARD treatment, clinical synovitis often resolved without intraarticular injections. These findings highlight the need for randomized clinical trials of the efficacy of intraarticular injections in modern RA treatment, to avoid unnecessary injections and optimize therapy.
